Company / R&D Expense
Bioventus Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$12.1M
FY2025
5-year range
$11.1M / $23.9M
FY2021-FY2025
Trend
-13.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 3 consecutive years, from $24M in FY2022 to $12M in FY2025.
Based on SEC 10-K filings.
$12M in FY2025 with a 3-year CAGR of -20.2%.
Declined from $19M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -20.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Bioventus Inc.'s r&d expense has declined for 3 consecutive years.
- 3-year CAGR of -20.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 13.2% year-over-year.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.1M | -13.2% |
| FY2024 | $14.0M | -26.7% |
| FY2023 | $19.0M | -20.2% |
| FY2022 | $23.9M | +115.8% |
| FY2021 | $11.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026